CA Patent

CA2732521A1 — Vasoconstriction compositions and methods of use

Assigned to Eye Therapies LLC · Expires 2010-02-04 · 16y expired

What this patent protects

The invention generally relates to topical and aerosolized compositions for inducing vasoconstriction with low incidence of rebound hyperemia The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volu…

USPTO Abstract

The invention generally relates to topical and aerosolized compositions for inducing vasoconstriction with low incidence of rebound hyperemia The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume The compositions preferably comprise brimonidine The compositions preferably have pH between about 5.5 and about 6.5.

Drugs covered by this patent

Patent Metadata

Patent number
CA2732521A1
Jurisdiction
CA
Classification
—
Expires
2010-02-04
Drug substance claim
No
Drug product claim
No
Assignee
Eye Therapies LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.